Order Article Reprints

Signorelli C, Calegari MA, Anghelone A, Passardi A, Gallio C, Bittoni A, Lucchetti J, Angotti L, Di Giacomo E, Zurlo IV, et al. Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study. Cancers. 2025; 17(12):2037. https://doi.org/10.3390/cancers17122037

Signorelli, Carlo, Maria Alessandra Calegari, Annunziato Anghelone, Alessandro Passardi, Chiara Gallio, Alessandro Bittoni, Jessica Lucchetti, Lorenzo Angotti, Emanuela Di Giacomo, Ina Valeria Zurlo, and et al. 2025. "Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study" Cancers 17, no. 12: 2037. https://doi.org/10.3390/cancers17122037

Signorelli, C., Calegari, M. A., Anghelone, A., Passardi, A., Gallio, C., Bittoni, A., Lucchetti, J., Angotti, L., Di Giacomo, E., Zurlo, I. V., Morelli, C., Dell’Aquila, E., Artemi, A., Gemma, D., Emiliani, A., Ribelli, M., Corsi, D. C., Arrivi, G., Mazzuca, F., ... Basso, M. (2025). Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study. Cancers, 17(12), 2037. https://doi.org/10.3390/cancers17122037